Adaptimmune has become one of the first firms to have a drug accepted into EMA’s PRIME regulatory fast-track initiative.
Pfizer has secured an exclusive option to acquire Western Oncolytics’ WO-12 once the oncolytic vaccinia virus has completed Phase I.
Almost all of the biotech IPOs that have priced since the first quarter have broken issue, meaning that they are now trading below their offer price
Celgene highlighted a handful of immuno-oncology deals that are driving its long-term R&D prospects including Juno and bluebird CAR-T partnerships.
Gene editing biotech Editas Medicine has signed a three-year R&D collab deal with Milan-based San Raffaele Telethon Institute for Gene Therapy to develop…
In our EuroBiotech roundup this week, Motif Bio sets IPO terms, MSP plans a £60 million laboratory development, Prokarium bags cash for plague R&D and more.
Regulus Therapeutics saw its shares nosedive last month when the FDA put a clinical trial hold on its leading hep C candidate RG-101--but the company said this…
AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…
Genmab and J&J bag a breakthrough designation, Merck dumps ALK, uniQure yo-yos on gene therapy data and more.
Shares in uniQure briefly hit a new low following a negative knee-jerk reaction to fresh data on its hemophilia B gene therapy.